| Drug Name |
Fedratinib |
| Drug ID |
BADD_D02554 |
| Description |
Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative.[A183188]
Fedratinib was granted FDA approval on August 16, 2019.[L8090] |
| Indications and Usage |
Fedratinib is indicated to treat adults with primary or secondary myelofibrosis that is either intermediate-2 or high risk.[L8090] |
| Marketing Status |
approved; investigational |
| ATC Code |
L01EJ02 |
| DrugBank ID |
DB12500
|
| KEGG ID |
D10630
|
| MeSH ID |
C528327
|
| PubChem ID |
16722836
|
| TTD Drug ID |
D0G8BM
|
| NDC Product Code |
Not Available |
| UNII |
6L1XP550I6
|
| Synonyms |
Fedratinib | N-tert-butyl-3-(5-methyl-2-(4-(2-(pyrrolidin-1-yl)ethoxy)phenylamino) pyrimidin-4-ylamino)benzenesulfonamide | TG101348 | SAR302503 | fedratinib hydrochloride | Inrebic |
